apollo

Select Address

0
  • Login

ATEZOLIZUMAB

About

ATEZOLIZUMAB is an anti-cancer medicine used in the treatment of unresectable, stage II-IIIa non-small cell lung cancer (NSCLC). ATEZOLIZUMAB is also used in combination with other cancer medicine for the treatment of metastatic NSCLC (bevacizumab, paclitaxel, carboplatin), extensive-stage small cell lung cancer and biliary tract cancer (carboplatin, etoposide), metastatic melanoma (cobimetinib, vemurafenib), and unresectable hepatocellular cancer (bevacizumab).

ATEZOLIZUMAB contains Atezolizumab, which belongs to the class of monoclonal antibodies. It works by inhibiting the action of a programmed death ligand receptor-1 (PD-L1), thereby stopping the abnormal growth of cancer cells.

ATEZOLIZUMAB may cause certain side effects such as fatigue, cough, diarrhoea, nausea, vomiting, tiredness, itching, rash, headache, fever, shortness of breath, muscle/joint pain, abdominal pain, loss of appetite and injection site reactions. Inform your doctor if any of these side effects persist for longer. ATEZOLIZUMAB will be administered by an oncologist trained in administering anti-cancer agents. 

Avoid receiving ATEZOLIZUMAB and inform your doctor if you are allergic to it or any other components of it. This medicine is known to cause embryo-fetal toxicity. Hence, it is not recommended for use in pregnancy. Avoid breastfeeding while taking this ATEZOLIZUMAB. Before starting treatment with ATEZOLIZUMAB, tell your doctor if you have/had liver or kidney disease, autoimmune disorders such as ulcerative colitis or Crohn's disease, a history of organ transplants, received an allogeneic stem cell transplant, or had radiation treatment to the chest, and myasthenia gravis.

Uses of ATEZOLIZUMAB

Treatment of Non-small cell lung cancer, Hepatocellular carcinoma, Biliary tract cancer, Small cell lung cancer and Metastatic melanoma

Medicinal Benefits

ATEZOLIZUMAB contains Atezolizumab, which is used in the treatment of different types of cancers. It works by inhibiting the action of a programmed death ligand receptor-1 (PD-L1) that causes the multiplication of cancer cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other body parts.

Directions for Use

ATEZOLIZUMAB will be administered by a trained oncologist in the hospital setting. Hence, do not self-administer. Your doctor will decide the dose and duration of the treatment based on the severity and type of cancer.

Storage

Store in a cool and dry place away from sunlight

Side Effects of ATEZOLIZUMAB

  • Nausea
  • Vomiting
  • Diarrhoea
  • Loss of appetite
  • Weakness
  • Cough
  • Fatigue
  • Headache
  • Fever
  • Back pain
  • Upper respiratory tract infections
  • Injection site reactions

In-Depth Precautions and Warning

Drug Warnings

To treat your condition effectually, continue receiving ATEZOLIZUMAB for the period that your doctor has prescribed. ATEZOLIZUMAB may cause severe immune-mediated adverse reactions (IMAR) such as immune-mediated colitis, hepatitis, hepatotoxicity, nephritis, endocrinopathies, pneumonitis, cardiac problems, and dermatologic reactions. It may also cause infusion-related reactions in some patients. Therefore, caution should be exercised if you have/had liver or kidney disease, any history of organ transplant, gastrointestinal disorders, autoimmune disorders such as ulcerative colitis or Crohn’s disease, lung disease, heart problems, and breathing difficulty while receiving ATEZOLIZUMAB. This medicine may also cause severe infusion-related reactions. Hence, careful monitoring is recommended and discontinue the treatment if any severe infusion reactions occur. Inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment, as this medicine is known to cause embryo-fetal toxicity. Breastfeeding should be discontinued in nursing mothers during the treatment as it passes into breast milk and may cause a possible risk to the infant. This medicine is not recommended for use in children below 12 years of age as the safety and efficacy are not established.

Drug Interactions

Drug-Drug Interactions: ATEZOLIZUMAB may have interaction with immunomodulator drugs (thalidomide), corticosteroids (prednisolone, methylprednisolone, prednisone), etc.

Drug-Food Interactions: Avoid alcohol consumption and smoking.

Dug-Disease Interactions: Tell your doctor if you have liver or kidney disease, heart problems, GI disorders, dermatitis, or a weak immune system before starting the treatment.

Drug-Drug Interactions Checker List:

  • THALIDOMIDE
  • PREDNISOLONE
  • METHYLPREDNISOLONE
  • Safety Advice

    • Safety Warning

      Alcohol

      consult your doctor

      It is unknown whether ATEZOLIZUMAB interacts with alcohol. Consult your doctor for more information.

    • Safety Warning

      Pregnancy

      unsafe

      ATEZOLIZUMAB is not recommended for use in pregnancy as it may cause embryo-fetal toxicity and harm your foetus. Hence, if you are pregnant or planning to be pregnant, inform your doctor before receiving ATEZOLIZUMAB. You should not become pregnant while you are receiving ATEZOLIZUMAB for at least five months from the last dose of ATEZOLIZUMAB. Using effective birth control methods while on treatment is suggested.

    • Safety Warning

      Breast Feeding

      unsafe

      ATEZOLIZUMAB should not be taken if you are breastfeeding, as it passes into breast milk and may harm your infant. Avoid nursing your child while on treatment with this medicine and for at least five months from the last dose of medicine.

    • Safety Warning

      Driving

      caution

      ATEZOLIZUMAB will be administered to hospitalized patients. Driving is not recommended.

    • Safety Warning

      Liver

      caution

      If you have pre-existing or a history of liver problems, tell your doctor before receiving this medicine. Inform your doctor if you experience any symptoms, such as severe nausea or vomiting, right-sided upper stomach pain, easy bruising or bleeding, dark urine, or jaundice (yellowing of the skin or eyes). Your doctor may suggest tests to monitor your liver function while on treatment with this medicine.

    • Safety Warning

      Kidney

      caution

      If you have a pre-existing or a history of kidney diseases, inform your doctor before receiving ATEZOLIZUMAB. Tell your doctor if you have little or no urination, swelling in your feet or ankles, or blood in your urine. Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.

    • Safety Warning

      Children

      unsafe

      ATEZOLIZUMAB is not recommended for use in children under 12 years old as the safety and efficacy are not established.

    Habit Forming

    No

    Diet & Lifestyle Advise

    • Physical activity helps strengthen muscles, reduces fatigue, aids in weight loss, and gives strength. Gentle activities like 20-30 minutes of walking or swimming would be helpful.
    • Maintain a healthy weight by performing regular low-strain exercises and eating healthy food.
    • Getting adequate sleep while resting helps improve your health and mental ability and improves attention.
    • De-stress yourself by meditating, reading books, taking a warm bubble bath, or listening to soothing music.
    • Eat food rich in antioxidants, such as berries, spinach, etc.
    • Foods containing fibre help with digestion. These include beans, peas, lentils, whole grains, nuts, and seeds.
    • Avoid smoking and alcohol consumption.
    • Maintain a healthy weight.

    Special Advise

    • Your doctor may suggest periodic liver function tests, kidney function tests, and lung function tests to monitor the function of the liver, kidney and lungs due to the use of ATEZOLIZUMAB.
    • Using contraceptive pills while using ATEZOLIZUMAB to prevent pregnancy is advised.
    • Thyroid function and adrenocorticotropic hormone levels will be monitored during treatment to avoid any life-threatening side effects.

    Patients Concern

    Disease/Condition Glossary

    Non-Small Cell Lung Cancer (NSCLC): It is the most common form of lung cancer, which occurs when cells that form the lining of the lung start growing uncontrollably. It is mostly seen in persons who smoke. Symptoms may include chest pain, weight loss, hoarseness, and difficulty breathing.

    Hepatocellular carcinoma: It occurs when the cancer/ malignant cells grow out of control in the liver. This infects the liver, destroys the liver cells and affects the ability of the liver to work properly. Symptoms may include abdominal pain, loss of appetite, weight loss, and pale bowel motions.

    Biliary tract cancer: Also known as bile duct cancer or Cholangiocarcinoma. It is a rare type of cancer in which the cancer cells grow abnormally in the epithelial cells lining the biliary tract. Symptoms may include abdominal pain, itching, fever, weight loss, changes in the colour of urine and stools, and jaundice.

    Metastatic Malignant Melanoma: Melanoma is a type of skin cancer in which the cancer cells grow in melanocytes. It is mainly caused by harmful UV radiation from the sun. Malignant melanoma is common in fair-skinned and freckled individuals. It results in mole formation, typically on the skin of the face. ATEZOLIZUMAB is used in combination with ipilimumab in adults and children above 12 years of age.

    FAQs

    ATEZOLIZUMAB is used to treat Non-small cell lung cancer, Hepatocellular carcinoma, Biliary tract cancer, Small cell lung cancer and Metastatic melanoma.

    ATEZOLIZUMAB contains Atezolizumab, which works by inhibiting the action of a programmed death receptor-1 (PD-L1) that causes the multiplication of cancerous cells.

    Available Medicines for

    ATEZOLIZUMAB

    VIEW MORE PRODUCTS